Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional Health Outcomes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2022
Price :
$35
*
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Pfizer; Progenics Pharmaceuticals; Salix Pharmaceuticals; Wyeth
- 26 Oct 2022 Results of pooled analysis from two studies(n=363, study 302;NCT00402038; study 4000;NCT00672477) investigating if baseline patient characteristics impact the safety and efficacy of Methylnaltrexone for Opioid Induced Constipation in Patients With Advanced Illness presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022
- 22 Dec 2021 According to Bausch Health Companies media release, data from a post-hoc analysis (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) supports the use of Salix s RELISTOR for patients with Opioid-Induced Constipation and advanced illness in the Emergency Department Setting
- 22 Dec 2021 According to Bausch Health Companies media release, results assessing safety and efficacy of a single methylnaltrexone dose using post hoc polled data from 3 trials (study 301, NCT00401362; study 302, NCT00402038; and study 4000, NCT00672477) published in The Journal of Emergency Medicine